Investor Presentation First Nine Months of 2022
75
Investor presentation First nine months of 2022
The cardiovascular trial, SELECT, addresses many comorbidities
that can be improved with weight management
Weight loss (%)
30
Improvements (examples)
20
10
0-5%
0
Improvements per weight loss bracket
5-10%
>15%
10-15%
Hypertension
X
Hyperglycaemia
X
Prevention of T2D
Dislipidaemia
X
Kidney disease
Cardiovascular Disease
NASH
CV mortality
X
NAFLD
GERD
HF
X
SELECT trial endpoints
✓ Primary
X Secondary
O Exploratory
PCOS
OSAS
Knee OA
T2D remission
T2D: Type 2 diabetes; NAFLD: Non-alcoholic fatty liver disease; PCOS: Polycystic ovary syndrome; NASH: Non-alcoholic steatohepatitis; GERD: Gastroesophageal reflux disease; OSAS: Obstructive sleep apnea syndrome; OA: Osteoarthritis
HF: Heart failure
Sources: Garvey WT et al. Endocr Pract 2016;22(Suppl. 3):1-203; Look AHEAD Research Group. Lancet Diabetes Endocrinol 2016;4:913-21; Lean ME et al. Lancet 2018;391:541-5; Benraoune F and Litwin SE. Curr Opin Cardiol 2011;26:555-61; Sundström J et al.
Circulation 2017;135:1577-85., Morales E and Praga M. Curr Hypertens Rep 2012;14:170-176
Novo NordiskⓇView entire presentation